Juliane Bernholz | CEO
A.M. Pharma

Dr. Juliane Bernholz is an experienced CEO, cell biologist, and molecular geneticist with over 30 years of leadership experience in the pharmaceutical industry having worked and lived in the US and multiple countries in Europe. Currently, she serves as the CEO of AM-Pharma, a private clinical stage biotech company located in the Netherlands, where she has been instrumental in developing innovative treatments for rare and critical care diseases, including Hypophosphatasia and Acute Kidney Injury. Prior to Dr. Bernholz’ role at AM-Pharma, she held senior leadership positions in R&D and Business Development at renowned companies such as Johnson&Johnson, Sanofi, Novartis and Actelion. Throughout her career, Dr. Bernholz has successfully led cross-functional teams, managed complex drug development programs, and driven strategic initiatives across small molecules, biologics, new modalities and cutting-edge therapies and has played a key role in bringing multiple therapies to market. Furthermore she has successfully negotiated, executed and chaired collaborations with industry and academia. With a strong foundation in scientific research, having worked under Nobel laureates and completed a PhD in Cell Biology, Dr. Bernholz is passionate about leveraging scientific innovation to improve patient outcomes. She has completed executive leadership programs at Wharton and IMD including a Board Diploma. Dr. Bernholz is dedicated to fostering collaboration and driving growth in the global pharmaceutical sector. Outside of work, she enjoys exploring diverse cultures, nature, and outdoor activities such as swimming, tennis, hiking and skiing. Dr. Bernholz has two grown up sons.